“A key takeaway from this study is that if someone has a proliferative disorder, in this case melanoma, doing shift work or regularly changing time zones could exacerbate the problem by dampening immune system response to tumor growth,” noted one researcher.
The goal of Precision Promise is to improve the speed at which effective drugs can come to market and reduce the overall cost of running clinical trials. It seeks to accomplish this by designing a clinical trial platform that tests multiple experimental therapies at the same time.
Both studies point to the IgG class of antibodies as the longest-lasting antibodies detectable in the blood and saliva of patients during this timeframe, suggesting that SARS-CoV-2-specific IgG antibodies may serve as promising targets to detect and evaluate immune responses against the virus.
Scribe’s platform is focused on engineering, delivering, and developing novel, custom CRISPR molecules. The company’s first technology, X-Editing (XE), provides greater editing activity, specificity, and deliverability than other CRISPR genome editing tools currently available.
A report from the Personalized Medicine Coalition found significant variability in the use of genomic testing for patients not only from state to state, but also within states.
While some have speculated that the Nobel Prize for CRISPR might come from the Physiology or Medicine committee, there was little doubt that, should a Nobel Prize for CRISPR be awarded in Chemistry, Doudna and Charpentier would claim two of the possible three slots.
The “one-pot” assay uses fluorescence-based detection of RNA from pathogens, can be performed within 30–50 minutes of incubation time, and can reach a limit of detection of 0.1-attomolar RNA concentration.
The way cancer mutations accumulate in the genome depends on both the 3D structure of the chromosome and the factor that is causing the mutation, which could help to guide treatment better as well as inform investigators searching for cancer causing mutations.
Studies have suggested that increasing the number of regulatory T cells—and therefore putting stronger “brakes” on the immune system—might help subdue symptoms of autoimmune diseases, while blocking regulatory T cells, or lifting these molecular brakes, could help the immune system better fight cancer.
Proceeds from the financing will allow SOPHiA to embark upon the next stage of its planned global expansion, aimed at satisfying growing clinical and biopharma demand for secure data pooling and knowledge sharing for healthcare professionals.